Cipla : Q3 FY22 Investor presentation

Investor Presentation

Q3FY22

January 25, 2022

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

Robust momentum across key markets; Strong traction in One- India and US business drive Q3FY22 performance

Overall Revenue

6%	Sustained traction across
branded & generic markets;
(Q3 YoY Growth	modest contribution of
in INR Terms)	covid products

One India

13%

Sustained momentum

(Q3 YoY Growth in across core therapies and

INR Terms)

traction in flagship brands

North America

Robust momentum in core business; strong traction in

respiratory portfolio

$150 Mn	7%

Overall EBITDA

EBITDA Margin

Continued strong margin

22.7%trajectory

SAGA

Overall SAGA	SA Private Market
4%	16%
(Q3 YoY growth in $ Terms)	(Q3 YoY growth in ZAR Terms)
International Markets & API
International	API
2%	27%

Q3FY22 Revenues

(Q3 YoY growth in $ Terms)

(Q3 YoY growth in $ Terms)

(Q3 YoY growth in $ Terms)

Strong capital structure and robust free cash flow generation continues in Q3FY22

Net Cash1 / Equity	Cash Balances2
	(INR Cr)
0.16	4,148
	3,750

0.11

Mar'21

Dec'21

Mar'21

Dec'21

• Strong operating profitability and prudent working capital management drives robust free cash flow generation
• Net cash positive position continues at Dec-21 end reflects strong balance sheet health

1. Net Cash = Total Cash balances - Total debt | 2. Includes cash and cash equivalents including fixed deposits with remaining maturity of less than 12 months, current investments and excludes unclaimed dividend balances

Continued portfolio expansion with long-term partnerships & launches across our strategic markets

US Generics

One India

South Africa

International

Markets

• Approval for Lanreotide injection 505 (b)(2)
• Albuterol total market share1 15.9%|Arformoterol total market share1 26.8%
• Launched Spirofy®; India's first pneumotach based portable wireless Spirometer for diagnosis of COPD and asthma
• Expanding portfolio breadth with 9 launches across men's health, Cardio and Diabetes, CNS, Infectious diseases, pain & cold and flu and vaccines
• 2 important respiratory products filed in Europe
• China manufacturing plant set-up completed

1. TRx market share data as per IQVIA week ending 21st December 2021